Analyst Price Target is $53.73
▲ +18.06% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $53.73, with a high forecast of $76.00 and a low forecast of $35.00. The average price target represents a 18.06% upside from the last price of $45.51.
Current Consensus is
The current consensus among 10 contributing investment analysts is to hold stock in PTC Therapeutics. This rating has held steady since December 2022, when it changed from a Buy consensus rating.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.